Adapalene

Drug Profile

Adapalene

Alternative Names: CD-271; Differin Gel 0.1%; Differin Gel 0.3%; Differin Lotion 0.1%; Differin XP

Latest Information Update: 28 Feb 2017

Price : $50

At a glance

  • Originator Galderma
  • Class Anti-inflammatories; Antiacnes; Keratolytics; Naphthalenes; Retinoids; Small molecules
  • Mechanism of Action Retinoic acid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acne vulgaris
  • No development reported Photodamage
  • Discontinued Multiple sclerosis

Most Recent Events

  • 16 Feb 2017 Maruho plans a open label, randomised trial for Acne vulgaris (Combination therapy, In adolescents, In adults) in Japan (UMIN000024874)
  • 26 Jul 2016 Adapalene (Differin® gel 0.1%) licensed to Maruho in Japan for commercialisation
  • 08 Jul 2016 Adapalene (Topical, gel,0.1%) has been designated as an Over-the-counter (OTC) product in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top